Evidence map›Paper›PMID 40956679›Full record

ArticleDeutsches Arzteblatt international2025

Psychoactive Substance Use in Germany: Findings From the Epidemiological Survey of Substance Abuse (ESA) in 2024.

Sally Olderbak, Regina Hollweck, Eva-Maria Krowartz, Justin Möckl, Eva Hoch

Abstract read
In one paragraph

Article in Deutsches Arzteblatt international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sally OlderbakIFT Center for Mental Health & Addiction Research, Munich, Germany
Regina HollweckIFT Center for Mental Health & Addiction Research, Munich, Germany
Eva-Maria KrowartzIFT Center for Mental Health & Addiction Research, Munich, Germany
Justin MöcklIFT Center for Mental Health & Addiction Research, Munich, Germany
Eva HochIFT Center for Mental Health & Addiction Research, Munich, Germany

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMonitoring the use of psychoactive substances and the prevalence of substance-related disorders in the general population enables estimation of the extent of substance abuse and its effects on health and society.

methodsData are from the Epidemiological Survey of Substance Abuse (ESA) for 2024 (n = 7534, aged 18-64 years). Prevalence rates were calculated for the use of tobacco, alcohol, cannabis, illegal drugs, and medications, and for individuals who met the DSM-IV criteria for dependency or abuse. Rates were extrapolated to the German resident population aged 18 to 64 (51 480 168 people).

resultsThe most commonly used substance was alcohol, with a 30-day prevalence of 68.6% (35.3 million people), followed by nonopioid analgesics (31.5%) and conventional tobacco products (21.8%). The 12-month prevalence of cannabis use was 9.8% (5.1 million people). Dependence prevalences were 4.2% for alcohol, 8.3% for tobacco, 1.0% for cannabis, 0.1% for amphetamines, 0.1% for cocaine, 2.8% for analgesics, and 1.5% for hypnotics and sedatives. Abuse prevalences were 5.6% for analgesics, 0.5% for cannabis, 0.1% for cocaine, 0.1% for amphetamines, 1.1% for hypnotics and sedatives, and 3.3% for alcohol.

conclusionThe use of psychoactive substances in Germany is still widespread. Because of the effects of psychoactive substance use on health and society, continual monitoring is essential for the early detection of trends and the institution of targeted preventive and interventional measures.

Indexed as

Psychotropic DrugsSubstance-Related DisordersAdolescentAdultAge DistributionComorbidityFemaleGermanyHealth SurveysHumansIllicit DrugsMaleMiddle AgedPrevalenceRisk FactorsSex DistributionIllicit DrugsPsychotropic Drugs

Identifiers

PMID40956679
PMCPMC13266569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.